Valeant (VRX) Enters Cash, Stock Bid for Allergan (AGN)

Edward Jones Downgrades Allergen (AGN) to Sell

Edward Jones downgraded Allergen (NYSE: AGN) from Hold to Sell.

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $163.65 yesterday.

Increasingly Unlikely Allergen (AGN) Stays Independent - Piper Jaffray

Piper Jaffray analyst David Amsellem boosted his price target on Neutral-rated Allergen (NYSE: AGN) from $109 to $164 amid takeover interest, saying staying independent is most likely not in the cards.

Amsellem commented, "In the wake of Valeant's hostile bid for Allergan, we... More

TD Securities Upgrades Valeant Pharmaceuticals (VRX) to Buy

TD Securities upgraded Valeant Pharmaceuticals (NYSE: VRX) from Hold to Buy with a price target of $160.00 (from $145.00). The change follows news it is teaming with Bill Ackman to acquire Allergan.

Analyst Lennox Gibbs said, "The proposed transaction could substantially... More

JPMorgan Upgrades Allergen (AGN) to Overweight

JPMorgan upgraded Allergen (NYSE: AGN) from Neutral to Overweight with a price target of $190.00 (from $130.00).

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $163.65 yesterday.

Argus Downgrades Allergen (AGN) to Hold

Argus downgraded Allergen (NYSE: AGN) from Buy to Hold with a price target of $130.00 (unchanged).

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $142.00 yesterday.

Allergan (AGN) Plans to Carefully Review Valeant (VRX) Offer

Allergan, Inc. (NYSE: AGN) today confirmed that it has received an unsolicited proposal from Valeant Pharmaceuticals International, Inc. (NYSE: VRX) to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant... More

Pharma M&A May be Entering Megadeals Phase, Says Goldman Sachs Analyst (AGN) (VRX) (PFE) (AZN) (ACT) (FRX)

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced Tuesday that it has submitted a merger proposal to the Board of Directors of Allergan, Inc. (NYSE: AGN) under which each Allergan share would be exchanged for $48.30 in cash and 0.83 shares of... More

Jefferies Starts Allergen (AGN) at Hold

Jefferies initiates coverage on Allergen (NYSE: AGN) with a Hold rating and a price target of $139.00. (NOTE: Came out before last night's offer from VRX/Pershing Square)

For an analyst ratings summary and ratings history on Allergen... More

Allergan, Inc. (AGN) Issues Statement on Purported Valeant and Pershing Square Offer

Late Monday, Allergan, Inc. (NYSE: AGN) issued a statement in response to news Valeant Pharmaceuticals (NYSE: VRX) and Pershing Square Capital plan to make a merger proposal. Allergan said they have yet to receive a offer and has had no discussions with either Valeant or Pershing Square with respect to this... More

Market Wrap: Next Ford CEO Speculated; Gold Merger Tarnishes; Sarepta Pops on DMD Treatment Timeline

Market wrap for April 21st

End of the Day: S&P 500 up 7.0 to 1,871.89; Dow Jones up 40.7 to 16,449.25; Nasdaq up 26.0 to 4,121.55

* Allergan, Inc. (NYSE: AGN) ripped higher late Monday... More

Allergan, Inc. (AGN) Bid Could Come In Just Above $45B

CNBC's David Faber reports that Valeant Pharmaceuticals' (NYSE: VRX) bid for Allergan, Inc. (NYSE: AGN) could come in just north of $45 billion, with 1/3 coming in cash.

NOTE: In his 13D filing, Ackman indicated that Valeant currently expects the cash component will total around $15 billion